Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.77 |
| ▸ | MAPT | P10636 | 4/20 | 0.63 |
| ▸ | RAF1 | P04049 | 8/20 | 0.60 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 4/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.55 |
| ▸ | BRAF | P15056 | 1/20 | 0.54 |
| ▸ | KDR | P35968 | 1/20 | 0.54 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.54 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.52 |
| ▸ | USP2 | O75604 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15574735 | 0.91 | RAB9A (0.63) | RAB9AKMT2APOLBGAAHTT | |
| SCHEMBL3182702 | 0.89 | MAPT (0.60) | RAB9AMAPTRAF1MAPK13NPC1 | |
| SCHEMBL13528796 | 0.87 | SMN1; SMN2 (0.68) | RAB9AMAPTNPC1KMT2ASMN1; SMN2 | |
| SCHEMBL3171767 | 0.85 | RAF1 (0.60) | RAB9AMAPTRAF1MAPK13KMT2A | |
| SCHEMBL3176365 | 0.84 | RAB9A (0.55) | RAB9AMAPTRAF1MAPK13KMT2A | |
| SCHEMBL3187436 | 0.83 | RAB9A (0.84) | RAB9AMAPTRAF1NPC1KMT2A | |
| SCHEMBL3176437 | 0.83 | RAF1 (0.64) | RAB9ARAF1MAPK13NPC1KMT2A | |
| SCHEMBL3176040 | 0.83 | KDR (0.54) | RAB9AMAPTRAF1MAPK13NPC1 | |
| SCHEMBL12806612 | 0.82 | RAB9A (0.46) | RAB9AMAPTNPC1KMT2AMAPK14 | |
| SCHEMBL3183112 | 0.82 | RAB9A (0.54) | RAB9AMAPTRAF1NPC1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7652022-B2 | N-(4-(4-(4-hydroxyphenylamino)-pyrimidin-6-yl)-oxyphenyl)-N'-(3-trifluoromethylphenyl)-urea; | NOVARTIS AG (CH) | 2010-01-26 | — | — | US | claimed |
| EP-1511730-B8 | DIARYL UREA DERIVATIVES USEFUL FOR THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | NOVARTIS AG (CH) | 2009-04-08 | — | — | EP | claimed |
| US-20060128734-A1 | Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases | FLOERSHEIMER ANDREAS | 2006-06-15 | — | — | US | claimed |
| EP-1511730-A2 | DIARYL UREA DERIVATIVES USEFUL FOR THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | Novartis AG (CH) | 2005-03-09 | — | — | EP | claimed |
| WO-2003099771-A2 | DIARYL UREA DERIVATIVES USEFUL FOR THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | NOVARTIS AG (CH) | 2003-12-04 | — | — | WO | claimed |
| US-20240108739-A1 | OLIGOMERIC COMPOUNDS BINDING SPECIFICALLY TO PROTEOGLYCANS | PHI PHARMA SA (CH) | 2024-04-04 | — | — | US | disclosed |
| EP-4262879-A1 | OLIGOMERIC COMPOUNDS BINDING SPECIFICALLY TO PROTEOGLYCANS | Phi Pharma SA (CH) | 2023-10-25 | — | — | EP | disclosed |
| CN-116648266-A | Oligomeric compounds that specifically bind to proteoglycans | 菲药物股份有限公司 | 2023-08-25 | — | — | CN | disclosed |
| WO-2022129627-A1 | OLIGOMERIC COMPOUNDS BINDING SPECIFICALLY TO PROTEOGLYCANS | PHI PHARMA SA (CH) | 2022-06-23 | — | — | WO | disclosed |
| EP-4015004-A1 | PROTEOGLYCAN SPECIFIC BRANCHED PEPTIDES | Phi Pharma SA (CH) | 2022-06-22 | — | — | EP | disclosed |
| US-20100280003-A1 | COMBINATIONS OF JAK INHIBITORS | COOKE NIGEL GRAHAM | 2010-11-04 | — | — | US | disclosed |
| US-7652022-B2 | N-(4-(4-(4-hydroxyphenylamino)-pyrimidin-6-yl)-oxyphenyl)-N'-(3-trifluoromethylphenyl)-urea; | NOVARTIS AG (CH) | 2010-01-26 | — | — | US | disclosed |
| US-7652022-B2 | N-(4-(4-(4-hydroxyphenylamino)-pyrimidin-6-yl)-oxyphenyl)-N'-(3-trifluoromethylphenyl)-urea; | NOVARTIS AG (CH) | 2010-01-26 | — | — | US | disclosed |
| US-20090156602-A1 | Organic Compounds | COOKE NIGEL GRAHAM | 2009-06-18 | — | — | US | disclosed |
| EP-1511730-B8 | DIARYL UREA DERIVATIVES USEFUL FOR THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | NOVARTIS AG (CH) | 2009-04-08 | — | — | EP | disclosed |
| EP-1511730-B1 | DIARYL UREA DERIVATIVES USEFUL FOR THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | NOVARTIS AG (CH) | 2008-12-10 | — | — | EP | disclosed |
| US-20080207591-A1 | Organic Compounds | MANLEY PAUL W | 2008-08-28 | — | — | US | disclosed |
| US-20060128734-A1 | Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases | FLOERSHEIMER ANDREAS | 2006-06-15 | — | — | US | disclosed |
| EP-1511730-A2 | DIARYL UREA DERIVATIVES USEFUL FOR THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | Novartis AG (CH) | 2005-03-09 | — | — | EP | disclosed |
| WO-2003099771-A2 | DIARYL UREA DERIVATIVES USEFUL FOR THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | NOVARTIS AG (CH) | 2003-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240108739-A1 | OLIGOMERIC COMPOUNDS BINDING SPECIFICALLY TO PROTEOGLYCANS | CD44, CSGALNACT1, LGALS3BP | RAB9A 3686/4885MAPT 1722/4885RAF1 4414/4885 |
| US-20100280003-A1 | COMBINATIONS OF JAK INHIBITORS | JAK2, JAK3, JAK1 | RAB9A 1323/4885MAPT 3528/4885RAF1 30/4885 |
| US-20080207591-A1 | Organic Compounds | FLT4, FLT1, FLT3 | RAB9A 4471/4885MAPT 2139/4885RAF1 885/4885 |
| US-20060128734-A1 | Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases | UCK2, PRKDC, PRKACA | RAB9A 1414/4885MAPT 1220/4885RAF1 171/4885 |
| US-20090156602-A1 | Organic Compounds | BTK, JAK2, JAK3 | RAB9A 2477/4885MAPT 2307/4885RAF1 52/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.